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The role of vanadium as a micronutrient and hypoglycaemic agent has yet to be fully clarified.The present study was undertaken to
investigate changes in the metabolism of iron and in antioxidant defences of diabetic STZ rats following treatment with vanadium.
Four groups were examined: control; diabetic; diabetic treated with 1mgV/day; andDiabetic treated with 3mgV/day.The vanadium
was supplied in drinking water as bis(maltolato) oxovanadium (IV) (BMOV). The experiment had a duration of five weeks. Iron
was measured in food, faeces, urine, serum, muscle, kidney, liver, spleen, and femur. Superoxide dismutase, catalase, NAD(P)H:
quinone-oxidoreductase-1 (NQO1) activity, and protein carbonyl group levels in the liver were determined. In the diabetic rats,
higher levels of Fe absorbed, Fe content in kidney, muscle, and femur, and NQO1 activity were recorded, together with decreased
catalase activity, in comparison with the control rats. In the rats treated with 3mgV/day, there was a significant decrease in fasting
glycaemia, Fe content in the liver, spleen, and heart, catalase activity, and levels of protein carbonyl groups in comparison with the
diabetic group. In conclusion BMOV was a dose-dependent hypoglycaemic agent. Treatment with 3mgV/day provoked increased
Fe deposits in the tissues, which promoted a protein oxidative damage in the liver.
1. Background
Diabetes is a pathological state that affects many metabolic
processes and is associated with alterations to antioxidant
defences and the metabolism of trace elements, which may
contribute to the development of the disease.
The role of vanadium (V) as a micronutrient for humans,
its essentiality, distribution, and toxicology, as well as its
biological and pharmacological activity, are still not fully
understood [1]. Rising levels of V in the environment,
together with growing interest in the pharmacological effects
of some of its compounds, have led to the study of V
metabolism becoming an important area of current research.
In plasma, V is boundmainly to transferrin and to a lesser
degree to other molecules, such as albumin [2–4]. Elsewhere,
it is distributed primarily in the bone, kidney, and liver [1, 2,
4]. However, its interactions with other elements are not well
understood.
Some V complexes have been shown to possess hypogly-
caemic or insulin-mimetic properties [5–8], butmany aspects
remain to be determined, such as the interactions with
other elements involved in antioxidant defence. Moreover,
weight training athletes are reported to use it to improve
performance [9]. According to some authors, V improves
glucose metabolism and prevents the oxidant damage caused
by diabetes [10].
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Table 1: Digestive and metabolic utilization of Fe on days 28–35 of study.
C DM DMV DMVH 𝑃test
Food intake (g/day) 15 ± 2 33 ± 2.4a 26.9 ± 2a,b 13.8 ± 1.1b,c 𝑃 < 0.001
Water intake (mL/day) 17 ± 4 324 ± 36a 191 ± 41a,b 14 ± 7b,c 𝑃 < 0.001
V intake (𝜇g/day) 1 ± 0.1 1.9 ± 0.1a 965 ± 104a,b 3228 ± 350a,b,c 𝑃 < 0.001
Fe intake (𝐼) (𝜇g/day) 668 ± 88 1472 ± 105a 1197 ± 89a,b 614 ± 50b,c 𝑃 < 0.001
Faecal excretion (𝐹) (𝜇g/day) 497 ± 75 1219 ± 106a 888 ± 50a,b 430 ± 78b,c 𝑃 < 0.001
Urinary excretion (𝑈) (𝜇g/day) 29 ± 8 118 ± 95a 103 ± 22a 47 ± 17a,b,c 𝑃 < 0.001
Absorbed (𝐴); 𝐴 = (𝐼 − 𝐹) (𝜇g/day) 171 ± 78 253 ± 56a 308 ± 68a 184 ± 59b,c 𝑃 < 0.01
Retained (𝑅); 𝑅 = [𝐼 − (𝐹 + 𝑈)] (𝜇g/day) 142 ± 79 134 ± 52 205 ± 66b 137 ± 64c NS
Values shown are means ± SD, C: control rats; DM: diabetic STZ rats; DMV: diabetic STZ rats treated with 1mgV/day; DMVH: diabetic STZ rats treated with
3mgV/day. aDifferent from group C; bdifferent from group DM; cdifferent from group DMV. P < 0.05. NS: not significant.
However, other authors have related V with prooxidant
effects [11, 12], because it does not normalize alterations in
the metabolism of various elements that are associated with
diabetes [12].Therefore, thewidespread use ofV as a potential
insulin-mimetic agent is subject to evaluation of the toxicity
associated with its prooxidant effect.
Diabetes has been associated with alterations in iron (Fe)
homeostasis both in humans and in animal models [13]. The
generation of reactive oxygen species by prooxidant metals
such as Femay be amechanismwhich aggravates this disease.
Previous studies have reported that diabetes produces an
accumulation of Fe in the tissues together with increased
excretion of this metal [14]. Concerning the effect of diabetes
on Fe content in the liver, opinions are mixed; some authors
have observed increased Fe [15], while others have found no
changes [11]. Little is known about the effects of exposure toV
on Femetabolism in diabetes [11] and therefore we consider it
important to studywhetherV-treated diabetic rats experience
alterations in the metabolism of Fe and in the activity of liver
enzymes related to antioxidant defence. The results obtained
will clarify the role of V as a micronutrient and the level of its
biological activity as an antidiabetic agent.
2. Materials and Methods
2.1. Animals and Diets. The experiment was carried out over
a period of five weeks. Male Wistar rats (Charles River
Laboratories, L’ Arbresle, France) weighing 190–220 g at
the beginning of the experimental period were randomly
distributed into four groups: control group (C): 9 healthy rats;
diabetic group (DM): 8 STZ-induced diabetic rats; diabetic
treated group (DMV): 8 STZ-induced diabetic rats treated
with 1mgV/d (administered as 6.2mg BMOV/d); and high-
dose diabetic group (DMVH): 8 STZ-induced diabetic rats
treated with 3mgV/d (administered as 18.7mg BMOV/d).
All groups were fed with the semisynthetic AIN-93
diet (which provided 44.5mg Fe and 60 𝜇gV/kg food) and
were allowed free access to drinking water (Milli-Q quality)
throughout the experimental period. In the DM, DMV,
and DMVH groups, type I diabetes was induced by sin-
gle intraperitoneal administration of streptozotocin (STZ)
(Sigma-Aldrich, St. Louis, MO, USA) at a dose of 60mg/kg
body weight, as a diabetogenic agent. Seven days later, the
induction of diabetes was confirmed by measuring blood
glucose levels on three occasions (9 a.m., 2 p.m., and 7 p.m.).
Animals with a glucose concentration (random glycaemia)
>13.8mmol/L and with polyuria, polydipsia, and hyperpha-
gia were considered diabetic [16].
In all cases, the BMOV solutionwas prepared and admin-
istered daily in the drinkingwater for 35 days, a sufficient time
for the effects of V to become apparent [11, 17, 18]. BMOVwas
synthesised according to published procedures [19]. During
the experimental period, the animals’ weight gain and intake
of food and water were monitored. Every day at 9 a.m., the
surplus water from the previous day was removed and the
amount consumed was calculated. Table 1 shows the water
and V intake.
On day 35, after overnight fasting, the rats were
anaesthetised by intraperitoneal injection of 5mg sodium
pentobarbital/100 g body weight (Sigma-Aldrich, St. Louis,
MO, USA) and exsanguinated by cannulating the posterior
aorta. Blood was collected and centrifuged at 1200×g for
15 minutes to separate the serum. The gastrocnemius mus-
cle, kidney, liver, spleen, heart, and femur were removed,
weighed, placed in preweighed polyethylene vials, and stored
at −80∘C. During the last seven days of the experimental
period, the faeces and urine were collected every 24 h and
stored at −80∘C in polyethylene bottles for subsequent analy-
sis. All animals were housed from day 0 of the experiment
in individual metabolic cages designed for the separate
collection of faeces and urine. The cages were located in a
well-ventilated, temperature-controlled room (21±2∘C) with
relative humidity of 40–60% and a 12-hour light:dark period.
The following biological indices were calculated:
absorbed as [I − F] and retained as [I − (F + U)], where I =
intake, F = faecal excretion, and U = urinary excretion.
All experiments were carried out in accordance with
Directional Guides Related to Animal Housing and Care
(European Community Council, 1986) and all procedures
were approved by the Animal Experimentation Ethics Com-
mittee of the University of Granada.
2.2. Analytical Methods. V and Fe in the diet, serum, and
tissues were determined by ICP-MS (Agilent 7500, Tokyo,
Japan) after digestion of the corresponding material using a
microwave oven (Milestone, Sorisole, Italy). All the plastic
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containers used in the analysis were previously cleaned with
superpure nitric acid and ultrapure water (18.2Ω) obtained
using a Milli-Q system (Millipore, Bedford, MA, USA). For
Fe determination, 0.2 g of the corresponding samples was
taken and 6mL of a mixture (1 : 1) of nitric acid (65%)
and hydrogen peroxide (30%), both of Suprapur quality
(Merck, Darmstadt, Germany), was introduced directly into
the microwaved vessels. The samples were then digested by
applying the following programme: power 1000W, 2min
ramp to 85∘C, 4min ramp to 135∘C, 5min ramp to 230∘C
held for 15min. After digestion, the extracts were collected
and made up to a final volume of 30mL with Milli-Q water
for subsequent analysis. Further dilutions of samples were
prepared when necessary. Similarly, for the analysis of V, 0.5 g
of each serum sample was treated with 8mL of a mixture
of nitric acid, hydrogen peroxide, and water in a 1 : 1 : 6 ratio
in the microwave digester. After digestion, the extracts were
collected and made up to a final volume of 10mL with Milli-
Q water for subsequent analysis. Calibration curves for Fe
and V were prepared using stock solutions of 1000mg/L of
each element (Merck), using Ga as an internal standard. The
internal standard was added to each sample in the same
conditions. Calibration curves were prepared using 5 points
with ranges of 0-1mg/L and 0-0.1mg/L for Fe and V, respec-
tively. The total metal content in the tissues was obtained by
interpolation in the corresponding graphs; for this purpose,
each sample was measured three times. The accuracy of the
method used was evaluated by comparison with certified
reference materials such as Seronorm (Billingstad, Norway)
and NIST 8414 (Gaithersburg, MD, USA) obtaining results
of 68.9 ± 2.4mg/kg for Fe and 0.00391 ± 0.00087mg/kg
for V, these values being in agreement with the certified
ones (estimated in the case of V) of 71.2 ± 9.2mg/kg
and 0.0050mg/kg, respectively. Additionally, spiking exper-
iments were conducted: the concentration of Fe was analysed
in three aliquots of the same sample, two of which had
previously been enriched with different concentrations of Fe:
0.25 and 1mg/L. The same procedure was carried out for V,
using in this case concentrations of 0.06 and 0.1mg/L. The
recoveries calculated were 92–98% in all cases.
Glycaemia levels were determined using the sensor
ACCU-CHEK AVIVA (Roche, Mannheim, Germany). Liver
samples were homogenised in an ice-cold buffer (100mM
Tris-HCl, 0.1mM EDTA, and 0.1% triton X-100 (v/v), pH
7.8) at a ratio of 1 : 9 (w/v). Homogenates were centrifuged at
30,000 rpm for 30min in a Centrikon H-401 (Germany) cen-
trifuge. After centrifugation, the supernatant was collected
and frozen at −80∘Cuntil analysed. All enzymatic assays were
carried out at 25 ± 0.5∘C using a Power Wavex microplate
scanning spectrophotometer (Bio-Tek Instruments, USA)
in duplicate in 96-well microplates (UVStar, Greiner Bio-
One, Germany). The enzymatic reactions were started by the
addition of the tissue extract. The specific assay conditions
were as follows.
Superoxide dismutase (SOD; EC 1.15.1.1) activity was
measured spectrophotochemically by the ferricytochrome
C method using xanthine/xanthine oxidase as the source
of superoxide radicals [20]. The method was adapted
according to Trenzado et al. [21]. The reaction mixture
consisted of 50mM potassium phosphate buffer (pH 7.8),
0.1mM EDTA, 0.1mM xanthine, 0.013mM cytochrome C,
and 0.024 IUmL−1 xanthine oxidase. One activity unit was
defined as the amount of enzyme necessary to produce a 50%
inhibition of the ferricytochrome C reduction rate measured
at 550 nm.
Catalase (CAT; EC 1.11.1.6) activity was determined










in 50mM potassium phosphate buffer
(pH 7.0).
NAD(P)H:quinone-oxidoreductase-1 (NQO1; EC 1.6.
99.2) activitywas determined bymeasuringDCPIP reduction
at 600 nm [23]. The reaction mixture contained 50mM
Tris-HCl (pH 7.6), 50𝜇M 2,6-dichlorophenol indophenol
(DCPIP), and 0.5mM NADH. A control reaction with
distilled water (three measures average) was assayed and
subtracted from each sample reaction. For these enzymes,
one unit of activity is defined as the amount of enzyme
required to transform 1 𝜇mol of substrate/min under the
above assay conditions.The levels of protein carbonyl groups
were assessed using Protein Carbonyl Kit (Cayman Chemical
Company, MI, USA). The protein content of the supernatant
solutions was determined by the Bradfordmethod [24], using
bovine serum albumin as the standard.
All biochemicals, including substrates, coenzymes, and
purified enzymes, were obtained from Roche (Mannheim,
Germany) or Sigma Chemical Co. (St. Louis, MO, USA). All
other chemicals came from Merck (Darmstadt, Germany)
and were of reagent grade.
2.3. Statistical Analysis. Descriptive statistical parameters
(means and standard deviations) were obtained for each
of the variables studied. Statistical comparisons among the
four groups were performed by the analysis of the variance
(ANOVA) test. For the bivariate analysis, Pearson’s coefficient
of correlation was calculated. All analyses were performed
using the Statistical Package for Social Science 15.0 (SPSS,
Chicago, IL, USA). Differences were considered statistically
significant at a probability level <5%.
3. Results
Table 1 shows the food, water, and V intake and the digestive
and metabolic utilisation of Fe. The diabetic rats showed an
increase in food andwater intake, in Fe excreted in faeces and
urine, and in Fe absorbed, but no changes were found in Fe
retained, compared to the nondiabetic control rats. Treatment
with 1mgV/d decreased the intake of food and water and the
faecal excretion of Fe and increased Fe retained compared to
those in the untreated diabetic rats. Treatment with 3mgV/d
decreased the intake of food and water, the faecal and urinary
excretion of Fe, and Fe absorbed and retained compared to
those in the diabetic untreated rats and to those in the diabetic
rats treated with 1mgV/d.The rats treated with 3mgV/d had
values of food and water intake, faecal excretion of Fe, and
Fe absorbed and retained similar to those of the controls.
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Table 2: Iron content in kidney, liver, spleen, muscle, heart, and femur (mg/kg dry tissue) on day 35.
C DM DMV DMVH 𝑃test
Kidney 255 ± 43 359 ± 74a 299 ± 51 290 ± 53 𝑃 < 0.05
Liver 404 ± 54 428 ± 65 505 ± 82a,b 530 ± 73a,b 𝑃 < 0.05
Spleen 3043 ± 646 1849 ± 718a 2410 ± 670 3918 ± 671a,b,c 𝑃 < 0.001
Muscle 50 ± 14 68 ± 19a 70 ± 14 a 46 ± 5b,c 𝑃 < 0.01
Heart 340 ± 26 353 ± 56 356 ± 44 420 ± 46a,b,c 𝑃 < 0.05
Femur 40 ± 4 61 ± 4a 69 ± 6a,b 64 ± 19a 𝑃 < 0.001
Values shown are means ± SD, C: control rats; DM: diabetic STZ rats; DMV: diabetic STZ rats treated with 1mgV/day; DMVH: diabetic STZ rats treated with
3mgV/day. aDifferent from group C; bdifferent from group DM; cdifferent from group DMV. 𝑃 < 0.05.
Table 3: Activity of superoxide dismutase (SOD), catalase (CAT), NAD(P)H: quinone-oxidoreductase-1 (NQO1), and protein carbonyl group
levels in the liver on day 35.
C DM DMV DMVH 𝑃test
SOD (U/mg protein) 685 ± 81 672 ± 83 743 ± 74 718 ± 70 NS
CAT (U/mg protein) 389 ± 97 295 ± 29a 402 ± 76b 733 ± 73a,b,c P < 0.001
NQO1 (mU/mg protein) 173 ± 72 269 ± 87a 242 ± 59 155 ± 57b,c P < 0.05
Protein carbonyl groups (pm/mg protein) 134 ± 33 130 ± 38 196 ± 40a,b 186 ± 21a,b P < 0.01
Values shown are means ± SD. C: control rats; DM: diabetic STZ rats; DMV: diabetic STZ rats treated with 1mgV/day; DMVH: diabetic STZ rats treated with
3mgV/day. aDifferent from group C; bdifferent from group DM; cdifferent from group DMV. P < 0.05. NS: not significant.
However, treatment with 3mgV/d provoked urinary losses
of Fe greater than those recorded for the controls.
Table 2 shows the Fe content in the tissues studied.
Diabetes provokes increased Fe levels in kidney, skeletal
muscle, and femur and decreased Fe content in the spleen.
Treatment with 1mgV/d increased Fe levels in liver and
femur, in comparison with those in the untreated diabetic
rats. Treatment with 3mgV/d restored Fe in the muscle to
levels similar to those of the control group but increased the
content of Fe in the liver, spleen, and heart versus that in
the controls and untreated diabetic rats. Moreover, this dose
increased Fe in spleen and heart, in comparison to that in the
group treated with 1mgV/d.
Table 3 shows the activities of SOD, CAT, NQO1, and
protein carbonyl group levels. There was a decrease in CAT
and an increase in NQO1 activity in the untreated diabetic
rats. The two doses of V tested reduced the activity of NQO1
and increased that of CATandprotein carbonyl groups versus
that in the controls and untreated diabetic rats.
The bivariate study revealed the existence of significant
relations, among which the following are particularly impor-
tant. V intake correlated negatively with Fe content in liver
(𝑟 = 0.46; 𝑃 < 0.01), heart (𝑟 = 0.43; 𝑃 < 0.05), and femur
(𝑟 = 0.55;𝑃 < 0.01).The intake of V also correlated positively
with the activity of CAT (𝑟 = 0.61; 𝑃 < 0.01) and protein
carbonyl group levels (𝑟 = 0.46; 𝑃 < 0.05).
4. Discussion
The doses of V used in the present study (1mgV/d, approx-
imately 5mgV/kg body weight/d, and 3mgV/d, approxi-
mately 15mgV/kg body weight/d) are low in comparison
with those administered in many other studies and much
lower than LD50 (lethal dose 50) (41–90mgV/kg body
weight) [10, 11, 25]. The sample size has been designed
according to most of the studies performed in this field
[2, 10, 11, 13, 14].
The hyperphagia associated with diabetes leads to
increased food (Fe) intake, which accounts for the increased
net absorption of Fe observed in the untreated diabetic group
[26]. Despite the high Fe absorption and high urinary losses
of Fe, the polyuria that accompanies diabetes meant that the
total amount of Fe retained in the untreated diabetic rats was
similar to that of the controls (Table 1).
The treatment of diabetic rats with 1mgV/d decreased
food intake (Fe intake) in comparison with that in the
untreated diabetic rats. It has been suggested that the decrease
in food intake could be because V heightens the effects
of leptin, thus reducing food intake [27]. Other authors
have suggested that the reduction in food and water intake
could be due to the fact that V reduces the increased
production of neuropeptide Y (NPY) that occurs in diabetes
[28]. However, in the treated animals the net quantity of
Fe retained increased (Table 1). In this group, there was a
reduction in faecal losses of the cation, which would account
for the increased amount of Fe retained, in comparison with
that in the untreated diabetic rats.
The dose of 3mg V/d administered to the diabetic rats
had a clear antidiabetic effect, normalizing glycaemia [12]
and reducing the hyperphagia (Fe intake) and polydipsia
that accompany diabetes; food and water intake approached
the levels found in the controls (Table 1). The reduced food
consumption was the main reason why the rats in this group
presented values of Fe absorbed similar to those of the
controls and significantly lower than those of the other groups
of diabetic rats.
In the group of untreated diabetic rats, the Fe content
increased in various tissues. Previous studies have also
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described increased Fe content in various organs, and in this
respect there is a high degree of agreement in the case of
the kidney [14, 15]. One study showed that renal transferrin
receptor expression increased in STZ-induced diabetic rats
[13], which could explain the accumulation of Fe observed
in the kidney (Table 2). Treatment with 3mgV/d produced a
significant increase in Fe content in the liver, heart, and spleen
(Table 2), possibly due to the erythropoietic suppression and
the greater uptake of Fe by hepatocytes, macrophages, and
cardiac myocytes. The increased Fe content in the heart
reveals the existence of Fe overload, because the heart is
an organ where Fe is deposited when the storage organs
become saturated. This overhead indicates a worsening of
the situation, which could cause malfunctions in the organs
affected.
The presence of metal ions (especially Fe) and the
activation of macrophages by cytokines and/or abnormal
metabolites are known to lead to an overproduction of
reactive oxygen species (ROS). To determine whether the
increased Fe in the liver affects the oxidative status of this
organ, we designed a study of the activity of enzymes (SOD,
CAT) directly related to the control of the iron-induced
ROS production (Table 3). In addition, NQO1 activity was
studied (Table 3). The activity of NQO1 increases in response
to xenobiotics, oxidants, heavy metals, and carcinogens,
which has led to the suggestion that the enzyme may offer
protection against the toxic effects of these agents [29]. In
order to determine whether the generationof ROS caused
protein oxidative damage, we examined protein carbonyl
group levels. These abnormal metabolites, too, favor the
production of ROS.The liver was chosen for this study due to
its importance in Fe metabolism and because the treatment
produced significant Fe deposits in this organ.
Our results showed that in the untreated diabetic rats
there were no changes in the activity of SOD, while CAT
decreased andNQO1 increased.These findings are consistent
with those of previous studies concerning SOD [30, 31] and
CAT [32]. The increased NQO1 activity in diabetic rats may
favor a decrease in the formation of reactive oxygen species,
whichwould explainwhyno changes in SODappear, together
with the decreased CAT activity in this group. Treatment
with 1mgV/d increased the hepatic content of Fe, which was
accompanied by nonsignificant increases in SOD, increased
hepatic CAT, and raised levels of protein carbonyl groups.
Treatment with 3mgV/d caused an increase in Fe content
in the tissues. Fe was deposited mainly in the kidney, liver,
spleen, and heart. This situation was accompanied by an
increase in CAT activity and a decrease in that of NQO1 in
the liver. Recent in vitro studies with HepG2 cells [33] have
shown that exposure to V (ammoniummetavanadate) at low
concentrations does notmodify the activity of NQO1 but that
the latter decreases when the dose is increased.These authors
suggested that V inhibits the gene expression of NQO1.
Although our study used a different V compound and
our results were obtained in vivo, they corroborated those
mentioned above; with a dose of 1mgV/d, no significant
changes were observed, whereas enzyme activity decreased
when the dose of 3mgV/d was used, in relation to that in
the untreated diabetic rats. Previous studies have shown that
V decreases GPx activity and increases malondialdehyde
levels in the livers of healthy rats [34] and of diabetic
rats treated with V [12]. The decrease in NQO1 and GPx
activity, together with the enlarged pool of liver Fe, may have
increased the production of hydroxyl radicals. The strong
CATactivity response appears to be insufficient to prevent the
increased formation of protein carbonyl groups, whichwould
suggest that the treatment provoked oxidative damage to the
liver proteins.
5. Conclusion
Our results showed that treatmentwith 3mV/d (administered
as 18.7mg BMOV/d) caused an iron overload in tissues that
impaired antioxidant defences and produced protein oxida-
tive damage in the liver. However, further studies are needed
to better determine the effects arising from these interactions
in order to determine optimum levels for pharmacological
use, thus reducing or preventing toxic effects.
Conflict of Interests
There is no conflict of interests related to the authors or
consortiummembers, since the project was funded by public
funds.This project is dedicated to basic research and there are
no commercial interests.
Acknowledgments
The authors are grateful for support received from the
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[31] G. Sadi and T. Güray, “Gene expressions of Mn-SOD and GPx-
1 in streptozotocin-induced diabetes: effect of antioxidants,”
Molecular and Cellular Biochemistry, vol. 327, no. 1-2, pp. 127–
134, 2009.
[32] M. A. Abou-Seif and A.-A. Youssef, “Evaluation of some
biochemical changes in diabetic patients,”Clinica Chimica Acta,
vol. 346, no. 2, pp. 161–170, 2004.
[33] G. Abdelhamid, A. Anwar-Mohamed,M.M. Elmazar, andA.O.
S. El-Kadi, “Modulation of NAD(P)H: Quinone oxidoreductase
by vanadium in human hepatoma HepG2 cells,” Toxicology in
Vitro, vol. 24, no. 6, pp. 1554–1561, 2010.
[34] C. Sanchez-Gonzalez, C. Bermudez-Peña, C. E. Trenzado et al.,
“Changes in the antioxidant defence and in selenium concen-
tration in tissues of vanadium exposed rats,” Metallomics, vol.
4, pp. 814–819, 2012.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
